| Literature DB >> 31354940 |
Abstract
Post-amputation phantom limb pain (PLP) is highly prevalent and very difficult to treat. The high-prevalence, high-pain intensity levels, and decreased quality of life associated with PLP compel us to explore novel avenues to prevent, manage, and reverse this chronic pain condition. This narrative review focuses on recent advances in the treatment of PLP and reviews evidence of mechanism-based treatments from randomized controlled trials published over the past 5 years. We review recent evidence for the efficacy of targeted muscle reinnervation, repetitive transcranial magnetic stimulation, imaginal phantom limb exercises, mirror therapy, virtual and augmented reality, and eye movement desensitization and reprocessing therapy. The results indicate that not one of the above treatments is consistently better than a control condition. The challenge remains that there is little level 1 evidence of efficacy for PLP treatments and most treatment trials are underpowered (small sample sizes). The lack of efficacy likely speaks to the multiple mechanisms that contribute to PLP both between and within individuals who have sustained an amputation. Research approaches are called for to classify patients according to shared factors and evaluate treatment efficacy within classes. Subgroup analyses examining sex effects are recommended given the clear differences between males and females in pain mechanisms and outcomes. Use of novel data analytical approaches such as growth mixture modeling for multivariate latent classes may help to identify sub-clusters of patients with common outcome trajectories over time.Entities:
Keywords: assessment; central sensitization; cortical reorganization; neuropathic pain; phantom limb pain; referred pain; treatment
Mesh:
Year: 2019 PMID: 31354940 PMCID: PMC6652103 DOI: 10.12688/f1000research.19355.1
Source DB: PubMed Journal: F1000Res ISSN: 2046-1402
Summary of the literature reviewed in this article investigating the treatment of phantom limb pain.
| Authors, year,
| Site (and
| Reason(s) for
| Mean time
| Treatment
| Treatment
| Main outcome
| Assessments | Findings | Risk of bias |
|---|---|---|---|---|---|---|---|---|---|
| Dumanian
| UE = 13%
| Trauma = 90%
| (Less than 1
| 1. Targeted
| N/A | Change in NRS worst
| Baseline
| No significant between-
| High risk |
| Malavera
| LE = 100% | Trauma = 100% | 7.8 years | 1. Active rTMS
| 20 stimuli of
| PLP intensity measured
| Baseline
| No significant between-
| Low risk |
| Brunelli
| AK = 73%
| Dysvascular = 70%
| 458
| 1. SAIPAN
| ~1 hour two
| 1. PLP intensity, rate,
| Baseline
| Significant group
| High risk |
| Finn
| AE = 40%
| Trauma = 100% | 4.5 months
| 1. MT
| 15 minutes
| PLP intensity measured
| Baseline
| No between-group
| High risk |
| Anaforoğlu
| BK = 100% | Trauma = 100% | 13.25
| 1. MT
| 15 minutes
| 1. PLP intensity measured
| Baseline
| Significant group
| High risk |
| Ol
| BK = 100% | Trauma = 100% | (15–32
| 1. MT
| 5 minutes
| PLP intensity measured
| Baseline
| No significant between-
| High risk |
| Ramadugu
| AE = 8%
| NR | NR | 1. MT
| 15 minutes
| PLP intensity measured
| Baseline
| No between-group
| High risk |
| Tilak
| UE = 26%
| NR | 45 days | 1. MT
| 20 minutes
| PLP intensity measured
| Baseline
| No significant between-
| High risk |
| Rothgangel
| AK = 61%
| Trauma = 32%
| ~35 months | 1. MT followed
| At least 10
| PLP frequency, duration,
| Baseline
| No significant between-
| High risk |
| Rostaminejad
| AK = 40%
| Diabetes = 45%
| (2–38 months) | 1. EMDR
| 12 one-hour
| PLP intensity measured
| Baseline
| No between-group
| High risk |
Results from interventions using targeted muscle reinnervation, repetitive transcranial magnetic stimulation (rTMS), mirror therapy (MT), augmented reality, and eye movement desensitization and repossessing (EMDR) therapy are summarized above. For each study, the site, reason, and mean time since amputation are shown. Treatment groups and duration as well as main outcome measures, times of assessment, and major findings are included. The final column describes the article’s global risk-of-bias rating as assessed by the Cochrane Collaboration’s tool [8]. UE and LE refer to upper and lower extremity amputations, respectively. AK, BK, AE, and BE refer to amputations performed above (A) and below (B) the knee (K) and elbow (E) joint. NR denotes information that was not reported by the author. NRS refers to the numeric 0–10 rating scale. BDI, Beck Depression Inventory; MH, mental health; N/A, not applicable; PF, physical functioning; PLP, phantom limb pain; SAIPAN, Santa Lucia Alleviation Intervention for Phantom in Amputees’ Neurorehabilitation; SF, social functioning; SF-36, 36-Item Short Form Survey; V, vitality.
Figure 1. Risk-of-bias [8] assessments for studies presented in the review of recent randomized controlled trials exploring treatment of phantom limb pain.
Randomization: randomization sequence generation; Blinding – P & P: blinding of participants and personnel; Blinding – Outcome: blinding of outcome assessment; Outcome data: incomplete outcome data.